Comparative Pharmacology
Head-to-head clinical analysis: PHENAPHEN 650 W CODEINE versus QDOLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENAPHEN 650 W CODEINE versus QDOLO.
PHENAPHEN-650 W/ CODEINE vs QDOLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetaminophen: Weak COX-1 and COX-2 inhibitor in CNS, antipyretic via hypothalamic heat-regulating center. Codeine: Prodrug converted to morphine; mu-opioid receptor agonist.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
Acetaminophen 650 mg and codeine 60 mg orally every 4 hours as needed for pain; maximum acetaminophen 3 g/day.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
None Documented
None Documented
Acetaminophen: 2-3 hours (normal liver function); prolonged in liver disease (up to 5-10 hours) or overdose. Codeine: 2.5-3.5 hours; active metabolite morphine ~2 hours. Clinical context: half-life affects dosing interval; accumulation in hepatic or renal impairment.
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Acetaminophen: renal excretion of conjugates (glucuronide ~55%, sulfate ~30%, cysteine/mercapturate ~4%), with <5% unchanged. Codeine: renal excretion as codeine (~10%), norcodeine (~10%), morphine (~10%), and their conjugates; total 70-90% in urine as glucuronide conjugates.
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Category D/X
Category C
Opioid Agonist
Opioid Agonist